You are here

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: February 2021 to March 2026

AbstractFullPdf
Feb 2021678678262
Mar 2021427427192
Apr 2021217218144
May 2021215215123
Jun 202119619690
Jul 202117117177
Aug 202116416472
Sep 202116516588
Oct 202118518582
Nov 202119719797
Dec 202116416458
Jan 202214515672
Feb 2022160178129
Mar 2022207212135
Apr 2022155159104
May 2022197201130
Jun 202215215792
Jul 202217117795
Aug 2022217223136
Sep 2022180181152
Oct 2022216218144
Nov 2022196200101
Dec 202213913981
Jan 2023166166134
Feb 2023195195116
Mar 2023182185148
Apr 202318818893
May 202313813891
Jun 202310210272
Jul 2023161163107
Aug 202312112164
Sep 2023808043
Oct 202313413580
Nov 202325826169
Dec 202322122249
Jan 202411011270
Feb 2024929259
Mar 2024144147267
Apr 202412012388
May 202411111167
Jun 202411912274
Jul 202416616975
Aug 202410810857
Sep 202410310565
Oct 202415015284
Nov 2024190191108
Dec 202415415565
Jan 2025204211147
Feb 2025296297107
Mar 2025185186140
Apr 2025216216131
May 2025192194133
Jun 202510010375
Jul 2025220
Feb 2026110
Mar 2026110
Total962497355534